Juvenile RA: Fewer disease flares with Adalimumab (TNF Antibody)
Adalimumab with or without Methotrexate in Juvenile Rheumatoid ArthritisN Engl J Med. 2008 Aug 21;359(8):810-20
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
This was a three part study designed to assess the effectiveness of Adalimumab, a fully human monoclonal anti-TNF antibody, in the treatment of juvenile rheumatoid arthritis. The study consisted of an open-label lead-in phase (where patients were stratified according to methotrexate use), a double-blind withdrawal phase (following the 16 week lead-in phase, patients with an ACR Pedi 30 response we...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE